Table Graph
   

mRNA vaccine (any) - first boost - versus mRNA vaccine - for COVID-19 prophylaxis (excluding children) pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 0.09 [0.04, 0.19]< 155%3 studies (-/3)100.0 %moderatenot evaluable moderatecrucial-
hospitalization or death 0.21 [0.12, 0.37]< 10%2 studies (-/2)100.0 %NAnot evaluable crucial-
confirmed COVID (any severity) 0.20 [0.13, 0.32]< 199%10 studies (1/9)100.0 %NAlow important-
hospitalization 0.11 [0.06, 0.19]< 149%5 studies (-/5)100.0 %NAnot evaluable important-
symptomatic Covid-19 0.37 [0.26, 0.54]< 197%3 studies (-/3)100.0 %NAnot evaluable important-
severe COVID-19 (FDA definition) 0.25 [0.01, 5.50]< 10%1 study (1/-)80.8 %NAnot evaluable non important-
severe COVID-19 occurrence 0.06 [0.05, 0.08]< 10%4 studies (1/3)100.0 %NAnot evaluable non important-

safety endpoints 00

arrhythmia 1.99 [0.07, 59.22]< 10%1 study (1/-)34.8 %NAnot evaluable non important-
hypertension 0.50 [0.02, 14.80]< 10%1 study (1/-)65.5 %NAnot evaluable non important-
Myocardial infarction 0.74 [0.17, 3.33]< 10%1 study (1/-)65.0 %NAnot evaluable non important-
pulmonary embolism 0.17 [0.01, 3.30]< 10%1 study (1/-)87.8 %NAnot evaluable non important-
stroke (non-specific, hemorrhagic, and ischemic) 0.99 [0.06, 15.88]< 10%1 study (1/-)50.2 %NAnot evaluable non important-

AE of interest endpoints 00

cerebral venous sinus thrombosis (CVST) 0.50 [0.02, 14.80]< 10%1 study (1/-)65.5 %NAnot evaluable important-
appendicitis 3.97 [0.18, 88.14]< 10%1 study (1/-)19.4 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons